Feature Channels: Pharmaceuticals

• share
• favorite_border

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Memory impairment associated with steroid use has been identified in a new study. The University of Bristol-led findings, published in PNAS, show great potential for the identification of drugs that could be adapted to treat certain memory disorders.

• share
• favorite_border

While legal cannabis products in the United States are required to report THC potency levels on their packaging those levels aren't necessarily accurate, which can have important implications for cannabis consumers. According to a new study from the University of Northern Colorado’s Department of Biological Sciences, researchers Mitchell McGlaughlin and Anna Schwabe found that the THC potency values reported on the packaging of cannabis samples from dispensaries across Colorado’s Front Range are substantially over-reported.

• share
• favorite_border

Below are some of the latest headlines in the new Avian Flu channel on Newswise.

• share
• favorite_border

The Linde Family Foundation has made a $10 million gift to launch the Center for Therapeutic Discovery at Dana-Farber Cancer Institute. This new center will be home to a new team devoted to the development of novel therapeutics for patients with rare and hard-to-treat cancers.

• share
• favorite_border

A new twist on a drug used to treat alcohol use disorder could double up as a treatment for stroke. Called “Carb” for short, this new formulation is designed to treat ischemic stroke, protect brain tissue against injury and minimize the size of a brain infarct.

• share
• favorite_border

Global pharmaceutical company Takeda has agreed to exclusively license a group of small molecules that target tau – a protein in which misfolding and aggregation are believed to be a cause of Alzheimer’s disease.

• share
• favorite_border

A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin system (RAS) as potential treatments for severe COVID-19. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), the virus that causes COVID-19, enters pulmonary and myocardial cells through binding of its spike protein to the human angiotensin-converting enzyme 2 (ACE2). ACE2 is a vital enzyme that controls blood pressure and blood flow to multiple organs, including the lungs, heart and kidneys.

• share
• favorite_border

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing the appointment of Steve Schaefer as President, North America, effective today, April 11. Mr. Schaefer joins Kyowa Kirin North America (KKNA) after holding key leadership roles at top pharmaceutical companies, including Takeda Pharmaceuticals and Eli Lilly and Company.

• share
• favorite_border

Beyond vaccines, mRNA offers immense potential to fight disease, but targeting the genetic material to specific diseased cells is challenging—requiring a new method. To meet this need, researchers at the Case Western Reserve University School of Medicine, with a Global Research Fellowship award from Moderna Inc., are developing a process that essentially uses bubbles to overcome the problem.

• share
• favorite_border

The Endocrine Society is deeply concerned about a Texas ruling that reverses the U.S. Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to treat Cushing’s syndrome and to end pregnancy safely and effectively.

• share
• favorite_border

St. Jude Children’s Research Hospital scientists developed a combination therapy for a leukemia subtype harboring rearrangements in the KMT2A gene. The approach overcomes the cancer’s drug resistance, without adding toxicity. The study appears in Proceedings of the National Academy of Science.

• share
• favorite_border

A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.

• share
• favorite_border

For patients with advanced bladder cancer who are medically unfit for standard treatment, a new intravesical (inside the bladder) chemotherapy delivery system called TAR-200 is safe and shows initial evidence of effectiveness, reports a study in the May issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

• share
• favorite_border

Studies of consciousness often run into a common conundrum of science—it’s hard to measure a system without the measurement affecting the system.

• share
• favorite_border

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

• share
• favorite_border

Researchers have developed a novel synthetic substance that has the potential to be a more effective and safer way of delivering drugs around the body.

• share
• favorite_border

• share
• favorite_border

In a new study published in the January issue of Autophagy, they found that after traumatic brain injury, the brain’s immune system cells’ internal recycling function slowed dramatically, allowing waste products to build up and interfere with recovery from injury.

• share
• favorite_border

• share
• favorite_border

Pangolins, unique scale-covered mammals, are drastically declining in numbers across Asia and Africa, largely due to illegal trade. Part of the trade, both legal and illegal, supports the traditional Chinese medicine market, which has attracted conservation attention.

• share
• favorite_border

A significant clinical trial under the direction of Michael Kappelman, MD, MPH, professor of pediatrics at UNC School of Medicine, found that patients receiving the tumor necrosis factor inhibitor adalimumab combined with a low dose of methotrexate, a second immunosuppressant, did better than those treated with infliximab alone. Patients who received infliximab, another tumor necrosis factor inhibitor, had similar outcomes with or without methotrexate.

• share
• favorite_border

A pesar de las directrices, el tratamiento de primera línea para el estado epiléptico a menudo es inadecuado. Los estudios sugieren que hasta dos tercios de los pacientes reciben dosis subclínicas de benzodiazepinas, ya sea antes de llegar a un hospital o durante el tratamiento hospitalario de emergencia. ¿Hay soluciones?

• share
• favorite_border

Anticancer drugs are pivotal to cancer treatment, but their toxicity may not always be limited to cancer cells, resulting in harmful side-effects.

• share
• favorite_border

A roundup of the latest medical discoveries and faculty news happening at Cedars-Sinai in March 2023.

• share
• favorite_border

A common anesthesia drug could be beneficial in reducing pressure inside the skull of children with traumatic brain injuries (TBI), according to a study published in Critical Care Medicine.

• share
• favorite_border

Ochsner Health Doctor of Pharmacy discusses Narcan use and availability.

• share
• favorite_border

As the U.S. Supreme Court considers a case involving a cholesterol lowering drug, Sean Tu, a West Virginia University College of Law professor, said he believes pharmaceutical companies manipulate the patent system to maintain monopoly rights.

• share
• favorite_border

• share
• favorite_border

The March special issue of SLAS Discovery deviates from its traditional focus on assay technology, disease area or molecular target to introduce and explore protocol articles – the newly accepted article type for outlining detailed scientific methods and procedures.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

A National Eye Institute-led team has identified a compound already approved by the U.S. Food and Drug Administration that keeps light-sensitive photoreceptors alive in three models of Leber congenital amaurosis type 10 (LCA 10), an inherited retinal ciliopathy disease that often results in severe visual impairment or blindness in early childhood.